June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Melatonin suppresses the long-term risk of cataract surgery in diabetic individuals: An AI based study with clinical corroboration
Author Affiliations & Notes
  • Vincent M Monnier
    Pathology and Biochemistry, Case Western Reserve University, Cleveland, Ohio, United States
  • Zhengxiang Gao
    Center for AI based drug design, Case Western Reserve University School of Medicine, Cleveland, Ohio, United States
  • Maria Gorenflo
    Lerner College of Medicine, Cleveland Clinic, Cleveland, Ohio, United States
  • David C Kaelber
    Center for Clinical Informatics Research and Education, The MetroHealth System, Cleveland, Ohio, United States
  • Rong Xu
    Center for AI based drug design, Case Western Reserve University School of Medicine, Cleveland, Ohio, United States
  • Footnotes
    Commercial Relationships   Vincent Monnier Revel Pharmaceuticals, Code I (Personal Financial Interest); Zhengxiang Gao None; Maria Gorenflo None; David Kaelber None; Rong Xu None
  • Footnotes
    Support  NEI Grant EY029297
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 2465. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Vincent M Monnier, Zhengxiang Gao, Maria Gorenflo, David C Kaelber, Rong Xu; Melatonin suppresses the long-term risk of cataract surgery in diabetic individuals: An AI based study with clinical corroboration. Invest. Ophthalmol. Vis. Sci. 2023;64(8):2465.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Age-related cataract is the leading cause of blindness worldwide and associated with impaired quality of life. Anti-cataract compounds can block its progression in animal models but their clinical validation is lacking. Thus, currently, no medication is approved or known to delay clinical cataract progression.

Methods :
We developed an AI-based drug discovery system for repurposing potential anti-cataract drugs among 2650 FDA approved drugs and used a retrospective cohort design leveraging multicenter electronic health records (EHRs) from TriNetX platform with 793,108 patients with diabetes and cataract.. The clinical efficacy of the top-10 drug candidates was ranked by our Ai based drug repositoning system. Hazard ratios (HR) with 95% confidence intervals (95% CI) was used to investigate cataract surgery risk at various time points after drug prescription (3, 5, 10, and 20 years).

Results : Among top-10 AI predicted repurposed candidate drugs, aspirin, acetylcysteine, melatonin, and ibuprofen were associated with a reduced 3, 5, 10 and 20-year cataract extraction risk in both male and female diabetic patients. At 20 years, adjusted hazard ratios (HR) were 0.83 [0.80-0.87], 0.78 [0.68-0.88], 0.83 [0.77-0.88], 0.78 [0.74-0.81], respectively. The relative risk of cataract surgery at 20 years was suppressed ~40%, 15%, 7% and 0-7% by melatonin, ibuprofen, acetylcysteine, and aspirin, respectively.

Conclusions : Four repositioned drugs have the potential to delay cataract progression in diabetes. Of these, melatonin appears to have the most robust and sustained potential in both genders. All four drugs share in common the ability to directly or indirectly inhibit cyclooxygenase-2 (COX-2), an enzyme that is increased by multiple cataractogenic stimuli.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×